Looking to invest?Looking to fundraise?All DealsOverview
Closed
Capital at risk.Please read risk warning.

Antev

Equity
EIS

Antev Limited (Antev) is a clinical-stage biopharmaceutical company focused on the development of a drug for prostate cancer, Teverelix TFA.

Target
£2,000,000

£

This is not a commitment. You will be asked to confirm in the next section.

Contact

Companies house

Twitter

Overview

Antev Limited (Antev) is a clinical-stage biopharmaceutical company focused on the development of a drug for prostate cancer, Teverelix TFA.

Antev have developed a substantially differentiated product, teverelix TFA, a long-acting injectable gonadotrophin-releasing hormone (GnRH) antagonist with a novel microcrystal formulation, which is able to overcome the historical problems of previous GnRH antagonist candidates while also reducing injection site reactions.

Antev have acquired a strong intellectual property estate and are expanding its patent protection. The company is currently preparing phase IIb clinical programmes for prostate cancer.

As a pre-revenue company, Antev seeks to increase shareholder value by progressing the development of teverelix TFA towards registration. Approval is anticipated from 2023 onwards.

Sonal Shah

Deal Manager

Sector:

Healthcare

Country:

United Kingdom

Stage:

Other

Minimum Funding:

£2,000,000

Target:

£2,000,000

Valuation:

£40,600,000

Share price:

£18.00

Team

This section is currently locked.

Please Sign Up or Log In to unlock.

Market

This section is currently locked.

Please Sign Up or Log In to unlock.

Investment

This section is currently locked.

Please Sign Up or Log In to unlock.

Updates

This section is currently locked.

Please Sign Up or Log In to unlock.

Questions

This section is currently locked.

Please Sign Up or Log In to unlock.

Documents

15 document(s) hidden

Originator

Originator: Envestors

Contact name: Oliver Woolley

Investment Focus: Equity, Debt

About: Envestors Private Investment Club (EPIC) is a network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.

Over 1000

Experienced investors

Over £100m

Funding raised

ABOUT

Envestors Channel Islands is part of Envestors Limited, an FCA regulated corporate finance adviser in the UK that operates an international network of sophisticated investors investing a minimum of £25,000 in high growth unquoted companies seeking £500,000 to £10m in equity funding.

FURTHER INFORMATION

DisclaimerPrivacy PolicyRisk Warning

IMPORTANT INFORMATION

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Envestors CI does not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.Please click here to see the full Risk Warning.

© 2020 Envestors CI. All rights reserved.

Powered by ENVESTRY

Sqreen | Runtime Application Protection

By using our site, you acknowledge that you have read and understand our Privacy and Cookie Policy